Literature DB >> 23639175

In vitro muscle contracture investigations on the malignant hyperthermia like episodes in myotonia congenita.

K Hoppe1, F Lehmann-Horn, S Chaiklieng, K Jurkat-Rott, O Adolph, W Klingler.   

Abstract

BACKGROUND: A common form of congenital myotonia, myotonia congenita (MC), is caused by mutations in the skeletal muscle Cl(-) channel gene type 1 (CLCN1). Due to the reduced Cl(-) conductance of the mutated channels, the patients may develop generalized muscle rigidity and hypermetabolism during general anaesthesia. The clinical symptoms resemble malignant hyperthermia (MH), which may lead to mistreatment of the patient.
METHODS: Muscle specimens of ADR mice (an animal model of MC) as well as of human individuals were used and exposed to potent ryanodine receptor type 1 (RyR1) activators and increasing K(+) concentration. Muscle force was monitored by a standardized diagnostic method for MH, the so-called in vitro contracture test.
RESULTS: Neither muscle of ADR mice nor MC muscle (murine and human myotonic muscle) showed pathological contractures after exposure to the potent RyR1 agonists caffeine and halothane. Increasing concentrations of K(+) had a dose-dependent preventive effect on myotonic stiffness.
CONCLUSION: We conclude that the adverse anaesthetic MH-like episodes observed in MC patients do not primarily originate from an altered Ca(2+) release in skeletal muscle. In MC muscle, this hypermetabolism is facilitated by a (pharmacologically induced) sustained depolarization due to an instable membrane potential. The in vitro results suggest that these patients benefit from tight K(+) monitoring because of the membrane potential stabilizing effect of K(+) .
© 2013 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23639175     DOI: 10.1111/aas.12126

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  7 in total

1.  Sodium channel slow inactivation as a therapeutic target for myotonia congenita.

Authors:  Kevin R Novak; Jennifer Norman; Jacob R Mitchell; Martin J Pinter; Mark M Rich
Journal:  Ann Neurol       Date:  2015-01-09       Impact factor: 10.422

2.  Elevation of extracellular osmolarity improves signs of myotonia congenita in vitro: a preclinical animal study.

Authors:  Kerstin Hoppe; Sunisa Chaiklieng; Frank Lehmann-Horn; Karin Jurkat-Rott; Scott Wearing; Werner Klingler
Journal:  J Physiol       Date:  2018-11-20       Impact factor: 5.182

Review 3.  [Pharmacogenetics in anesthesia and intensive care medicine : Clinical and legal challenges exemplified by malignant hyperthermia].

Authors:  W Klingler; E Pfenninger
Journal:  Anaesthesist       Date:  2016-05       Impact factor: 1.041

4.  Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.

Authors:  Jean-François Desaphy; Roberta Carbonara; Teresa Costanza; Diana Conte Camerino
Journal:  Exp Neurol       Date:  2014-03-05       Impact factor: 5.330

5.  Hypermetabolism in B-lymphocytes from malignant hyperthermia susceptible individuals.

Authors:  Kerstin Hoppe; Guido Hack; Frank Lehmann-Horn; Karin Jurkat-Rott; Scott Wearing; Alberto Zullo; Antonella Carsana; Werner Klingler
Journal:  Sci Rep       Date:  2016-09-20       Impact factor: 4.379

6.  Paxilline Prevents the Onset of Myotonic Stiffness in Pharmacologically Induced Myotonia: A Preclinical Investigation.

Authors:  Kerstin Hoppe; Tina Sartorius; Sunisa Chaiklieng; Georg Wietzorrek; Peter Ruth; Karin Jurkat-Rott; Scott Wearing; Frank Lehmann-Horn; Werner Klingler
Journal:  Front Physiol       Date:  2020-11-23       Impact factor: 4.566

7.  A novel mutation of the CLCN1 gene in a cat with myotonia congenita: Diagnosis and treatment.

Authors:  Christian Woelfel; Kathryn Meurs; Steven Friedenberg; Nicole DeBruyne; Natasha J Olby
Journal:  J Vet Intern Med       Date:  2022-07-11       Impact factor: 3.175

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.